創新醫療(002173.SZ):富浙資本已增持1.39%的股份
格隆匯 7 月 14日丨創新醫療(002173.SZ)公佈,公司於2020年7月14日收到公司股東浙江富浙資本管理有限公司(“富浙資本”)郵件及傳真送達的《關於增持創新醫療管理股份有限公司股份的告知函》,富浙資本基於對公司未來持續發展的信心,於2020年5月7日至2020年7月13日期間,通過深圳證券交易所繫統集中競價方式累計增持上市公司股份631.3203萬股,佔公司總股本的1.39%。
富浙資本系浙商創投股份有限公司(“浙商創投”)第二大股東,持有浙商創投股份比例19.53%,公司股東陳越孟系浙商創投的實際控制人,股東杭州昌健投資合夥企業(有限合夥)(“昌健投資”)、杭州嵐創投資合夥企業(有限合夥)(“嵐創投資”)系浙商創投控制的企業,根據《上市公司收購管理辦法》第八十三條的相關規定,公司股東陳越孟、昌健投資、嵐創投資以及富浙資本為一致行動人。
截至目前,陳越孟持有公司股份848.8964萬股,昌健投資持有公司股份3395.5857萬股,嵐創投資持有公司股份1273.343萬股,陳越孟及其控制的昌健投資、嵐創投資合計持有公司股份5517.8251萬股,佔公司總股本的比例為12.13%。此次富浙資本增持公司股份後,上述股東共同控制公司股份6149.1454萬股,佔公司總股本的13.52%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.